Tessellate Bio discovers synthetic-lethal precision oncology drugs beyond HRD, pairs them with companion diagnostics, and licenses programs to pharma partners.
Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, today announces the appointment of Dr. Katie Chapman as Chief Scientific Officer (CSO).
Boehringer Ingelheim partners with Tessellate Bio to integrate a synthetic lethal program into its oncology pipeline. The collaboration includes a deal valued at over **500 million euros ($570 million)**. This move strengthens Boehringer’s focus on advancing targeted cancer therapies through synthetic lethality mechanisms.
Boehringer Ingelheim partners with Tessellate Bio to develop precision cancer treatments targeting **ALT-positive tumors**, which rely on alternative lengthening of telomeres for survival. The collaboration focuses on advancing therapies for cancers that use this mechanism to sustain growth. The deal includes over **$573 million** in upfront and milestone payments.
Apr 2025Endpoints NewsNews article
Dr Lara Boydpharmatimes.com/appointments/dr-lara-boyd/
Tessellate BIO names Dr Lara Boyd as its new Chief Business Officer. The appointment expands the biotech firm’s leadership team amid growth initiatives. Boyd brings expertise in business strategy and operational scaling to the company.
